Last update: Aug. 6, 2017
Minimal risk for breastfeeding and infant.
Alpha-glucosidase inhibitor which acts within the gastrointestinal tract without being absorbed, reducing intestinal absorption of glucose. Very low risk of hypoglycemia in monotherapy.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (moderately elevated molecular weight and very low intestinal absorption) make it unlikely that it would pass to breast milk in significant amounts (Serrano 2014, Everett 1997).
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM